ImmunityBio Inc. (IBRX)

ImmunityBio's stock has fallen sharply over the past month, down 35.82%, and sits 22.43% below its 50-day average and 15.33% below its 200-day average. The slide follows a November 9, 2026 quarterly report in which adjusted EPS of -$0.09 missed the analysts' estimate of -$0.05, and the stock fell 5.13% in the next session. Revenue still grew 52.30% year on year, but the company remains far from profit: its net profit margin is -607.79%. CleaRank rates the stock Sell with a score of 39/100, more cautious than the Strong Buy consensus from the four analysts who cover it, all of whom rate it Buy. The gap between those two views is the central question for the stock now.

The stock fell 5.13% in the first session after the November 9, 2026 report, when adjusted EPS came in at -$0.09 against an analyst estimate of -$0.05, a miss of 80.00%. It was the company's third miss in the last four reports, and the pattern matters for how investors weigh the rest of the record. Of the eight recent reports, only three beat the EPS estimate, and only one of those beats was followed by a lower share price. The August 4, 2026 report also missed badly, with EPS of -$0.22 against -$0.08 expected, and the stock rose 4.32% the next session. Earnings reactions have been inconsistent, so the November drop is one data point rather than a settled pattern.

Analysts expect revenue this fiscal year to reach $226.6M, a rise of 100.0%. Growth on that scale is the core of the bull case. Against it stand losses that are large relative to sales: the operating margin is -159.68% and the net profit margin is -607.79%. The GAAP EPS over the last twelve months is -$0.96, and the analysts' average estimate for this fiscal year is -$0.92. Revenue growth is real, but the company still spends far more than it takes in.

At a market capitalisation of $7.2B and a price-to-sales ratio of 39.30, the stock trades at more than ten times the sector median price-to-sales of 3.4. With no profit to measure against, the premium rests entirely on expected growth. Insiders sold $9.4M of stock over the last 18 months across 12 sales, and recorded no open-market purchases over the same period. Insider sales are often planned in advance or made to cover tax on vesting shares, so they are a weaker signal than purchases would be, but the absence of any buying by insiders is worth noting.

The stock is below both its 50-day simple moving average of $8.70 and its 200-day simple moving average of $8.00 at $7.97, and the 50-day average remains 9.16% above the 200-day average. The 14-day RSI of 36.6 sits in the bearish zone, and the MACD line is negative. Over one month the stock is down 35.82% and over one week it is down 18.64%, while the one-year return of 212.27% shows how much of the stock's rise came before the recent slide. The stock is still well above its 52-week low of $1.95, so the year's gains have not been erased, but the recent direction is clearly down.

The base case is that the stock keeps trading below its moving averages until it shows either a narrower loss or a sustained recovery in trend. For that to change, the price would need to reclaim the 200-day average at $7.97 and then the 20-day EMA at $8.34, which would be the first signs that selling pressure is easing. Analysts' median 12-month target of $14.50 sits well above the current price, with a range from $12.00 to $16.00, and all four firms reaffirmed Buy ratings as recently as October 15, 2026. Those targets only become meaningful if the company narrows its losses, since the analysts' average EPS estimate for this fiscal year is -$0.92 and the stock's negative earnings keep the valuation stretched, with a price-to-sales ratio of 39.30 against a sector median of 3.4. A further fall through the 52-week low at $1.95 would contradict the current trend and would likely reflect a sharp loss of confidence. Simulations from past volatility are not forecasts, and the stock's typical daily move of 6.28% means large swings are normal here.

Support sits at the 52-week low of $1.95, the nearest level below the price and a long way down, which marks the bottom of the stock's one-year range. Resistance comes first at the 200-day simple moving average of $7.97, the nearest level above the price, followed by the 20-day exponential moving average at $8.34 and the 50-day simple moving average at $8.70. The 52-week high of $12.43 is the furthest level above. Because the price is below all of these averages, a rally would have to clear $7.97 and $8.34 before the trend picture improves.